Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
Galectin Therapeutics (NASDAQ:GALT) has announced its upcoming presentation at the EASL 2025 Congress in Amsterdam, Netherlands, scheduled for May 7-10, 2025. The company will deliver a late-breaking oral presentation featuring data from their NAVIGATE study, which evaluates belapectin, a galectin-3 inhibitor, in patients with MASH cirrhosis and portal hypertension.
The presentation, titled 'Belapectin at 2 mg/kg/LBW Reduces Varices Development in MASH Cirrhosis with Portal Hypertension: Results from the NAVIGATE Trial,' will be presented on May 10, 2025. The company continues to analyze biomarker data, including 18-month trial data and results from 57 subjects who completed 36 months of treatment. Additional results are expected in Q2 2025.
Galectin Therapeutics (NASDAQ:GALT) ha annunciato la sua prossima presentazione al Congresso EASL 2025 ad Amsterdam, Paesi Bassi, previsto dal 7 al 10 maggio 2025. L'azienda terrà una presentazione orale a carattere di novità, mostrando i dati dello studio NAVIGATE, che valuta belapectina, un inibitore della galectina-3, in pazienti con cirrosi MASH e ipertensione portale.
La presentazione, intitolata 'Belapectina a 2 mg/kg/LBW riduce lo sviluppo di varici nella cirrosi MASH con ipertensione portale: risultati dello studio NAVIGATE', si terrà il 10 maggio 2025. L'azienda continua ad analizzare i dati dei biomarcatori, inclusi quelli a 18 mesi di studio e i risultati di 57 soggetti che hanno completato 36 mesi di trattamento. Ulteriori risultati sono attesi nel secondo trimestre del 2025.
Galectin Therapeutics (NASDAQ:GALT) ha anunciado su próxima presentación en el Congreso EASL 2025 en Ámsterdam, Países Bajos, programada del 7 al 10 de mayo de 2025. La compañía realizará una presentación oral de última hora con datos de su estudio NAVIGATE, que evalúa el belapectín, un inhibidor de galectina-3, en pacientes con cirrosis MASH e hipertensión portal.
La presentación, titulada 'Belapectín a 2 mg/kg/LBW reduce el desarrollo de varices en cirrosis MASH con hipertensión portal: resultados del ensayo NAVIGATE', se realizará el 10 de mayo de 2025. La compañía continúa analizando los datos de biomarcadores, incluidos los datos del ensayo a 18 meses y los resultados de 57 sujetos que completaron 36 meses de tratamiento. Se esperan resultados adicionales en el segundo trimestre de 2025.
Galectin Therapeutics (NASDAQ:GALT)는 2025년 5월 7일부터 10일까지 네덜란드 암스테르담에서 개최되는 EASL 2025 학술대회에서 발표할 예정임을 발표했습니다. 회사는 MASH 간경변증 및 문맥 고혈압 환자를 대상으로 한 갈렉틴-3 억제제인 벨라펙틴에 대한 NAVIGATE 연구 데이터를 포함한 최신 구두 발표를 진행할 예정입니다.
'Belapectin at 2 mg/kg/LBW Reduces Varices Development in MASH Cirrhosis with Portal Hypertension: Results from the NAVIGATE Trial'라는 제목의 발표는 2025년 5월 10일에 진행됩니다. 회사는 18개월 임상 데이터와 36개월 치료를 완료한 57명의 피험자 결과를 포함한 바이오마커 데이터를 계속 분석 중이며, 추가 결과는 2025년 2분기에 발표될 예정입니다.
Galectin Therapeutics (NASDAQ:GALT) a annoncé sa prochaine présentation au Congrès EASL 2025 à Amsterdam, aux Pays-Bas, prévu du 7 au 10 mai 2025. La société présentera une communication orale de dernière minute présentant les données de son étude NAVIGATE, qui évalue le belapectine, un inhibiteur de la galectine-3, chez des patients atteints de cirrhose MASH avec hypertension portale.
La présentation, intitulée « Belapectine à 2 mg/kg/LBW réduit le développement des varices dans la cirrhose MASH avec hypertension portale : résultats de l’essai NAVIGATE », aura lieu le 10 mai 2025. La société continue d’analyser les données des biomarqueurs, y compris les données à 18 mois de l’essai et les résultats de 57 sujets ayant complété 36 mois de traitement. D’autres résultats sont attendus au deuxième trimestre 2025.
Galectin Therapeutics (NASDAQ:GALT) hat seine bevorstehende Präsentation auf dem EASL 2025 Kongress in Amsterdam, Niederlande, angekündigt, der vom 7. bis 10. Mai 2025 stattfindet. Das Unternehmen wird eine kurzfristige mündliche Präsentation mit Daten aus der NAVIGATE-Studie halten, die Belapectin, einen Galectin-3-Inhibitor, bei Patienten mit MASH-Zirrhose und portaler Hypertonie bewertet.
Die Präsentation mit dem Titel 'Belapectin bei 2 mg/kg/LBW reduziert die Entwicklung von Varizen bei MASH-Zirrhose mit portaler Hypertonie: Ergebnisse der NAVIGATE-Studie' findet am 10. Mai 2025 statt. Das Unternehmen analysiert weiterhin Biomarkerdaten, einschließlich der 18-Monats-Daten der Studie und der Ergebnisse von 57 Probanden, die 36 Monate Behandlung abgeschlossen haben. Weitere Ergebnisse werden im zweiten Quartal 2025 erwartet.
- None.
- None.
NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the EASL 2025 meeting and deliver a scientific presentation in the late-breaking oral presentation session. The meeting will be held May 7-10, 2025, in Amsterdam, Netherlands.
“We are excited that data from our NAVIGATE study, evaluating belapectin, a galectin-3 inhibitor, in patients with MASH cirrhosis and portal hypertension, has been accepted as a late-breaking oral presentation. The selection of our abstract for an oral late-breaking session underscores the significance of these findings within the hepatology community. Through our belapectin program, we continue to advance understanding of liver cirrhosis — a condition that has long been overlooked despite its profound impact on patients’ lives. We’re looking forward to sharing the data with the scientific community at the EASL Congress. Additionally, we continue to analyze biomarker data from NAVIGATE, including the stand-alone 18-month trial data, as well as the 57 subjects completing 36-months. As patients are no longer being treated, we expect to share additional results in the second quarter of 2025.” said Dr. Khurram Jamil, Chief Medical Officer at Galectin Therapeutics.
Poster Presentation Details
Title: Belapectin at 2 mg/kg/LBW Reduces Varices Development in MASH Cirrhosis with Portal Hypertension: Results from the NAVIGATE Trial
Abstract Number: LB-006/ LB25183
Session: Poster, Complication of Cirrhosis, Portal Hypertension
Authors: Naim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, Mitchell Shiffman, Eric J. Lawitz, Edward Mena, Nadege Gunn, Khurram Jamil, Stephen A. Harrison, Naga Chalasani
Date, time & location: Saturday, May 10, 2024: 1:00 PM - 2:30 PM, CET RAI Amsterdam
The presentation will be available for viewing by EASL attendees and will be posted on our website under the “Events & Presentations” page shortly after the congress.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect”, “look forward”, “believe”, “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not product positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Investors Relations Contacts:
Kevin Gardner
kgardner@lifesciadvisors.com
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.
FAQ
When will Galectin Therapeutics (GALT) present at EASL 2025 Congress?
What are the key findings of GALT's NAVIGATE trial being presented at EASL 2025?
How many patients completed the 36-month NAVIGATE study for GALT's belapectin?
When will GALT release additional NAVIGATE trial results?
What condition does GALT's belapectin target in the NAVIGATE study?
